市場調查報告書
商品編碼
1470873
患者異質骨移植/PDX 模型市場:按類型、腫瘤類型、應用和最終用戶 - 2024-2030 年全球預測Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
患者來源的異質骨移植/PDX模型市場規模預計2023年為2.2226億美元,2024年達到2.5351億美元,2030年將成長至5.7499億美元,預計複合年成長率為14.54%。
患者來源的異種移植模型(PDX)是一種前沿的癌症研究模型,將人類腫瘤組織和細胞直接移植到免疫力缺乏或人源化小鼠體內,以在體內生長和維持患者的腫瘤,成為一種藥物開發工具。全球癌症發生率不斷上升,增加了對有效治療方法的需求,並增加了對研發活動的投資。然而,與獲取患者組織樣本相關的倫理和監管問題以及人類和小鼠之間的生理差異限制了患者來源的異種移植(PDX)模式的發展。此外,政府對癌症研究的資助增加以及分子表徵技術的進步預計將在未來創造利潤豐厚的機會。
主要市場統計 | |
---|---|
基準年[2023] | 2.2226億美元 |
預測年份 [2024] | 25351萬美元 |
預測年份 [2030] | 57499萬美元 |
複合年成長率(%) | 14.54% |
小鼠模型廣泛用於腫瘤學中以開發新的療法。
小鼠模型是使用最廣泛的 PDX 模型,因為它們體積小、易於操作且在基因上與人類相似。這些模型對腫瘤生物學的理解和腫瘤學新治療方法的發展做出了重大貢獻。另一方面,大鼠模型由於其體積大以及在外科手術、影像診斷和採樣方面的優勢,已成為小鼠 PDX 模型的有價值的替代品。此外,大鼠在模擬某些人類癌症類型(例如神經膠質瘤和肉瘤)時表現出更多樣化的免疫反應和更高的保真度。
腫瘤類型:專注於婦科腫瘤模型,研究婦科癌症。
胃腸道 (GI) 腫瘤模型對於研究影響消化器官系統(例如大腸直腸癌、胃癌和胰腺癌)至關重要。這些模型可用於研究腫瘤發展和轉移的潛在機制以及評估潛在的治療方法。婦科腫瘤模型對於婦科癌症(包括卵巢、子宮內膜癌和子宮頸癌)的研究至關重要。血液腫瘤模型用於研究血液癌症,如白血病、淋巴瘤和多發性骨髓瘤。呼吸道腫瘤模型對於研究肺癌的病理和治療方法至關重要。泌尿系統腫瘤模型對於研究泌尿器官系統癌症(例如膀胱癌、腎臟癌和前列腺癌)非常重要,它可以讓研究人員了解疾病的發展並確定個人化的治療策略。
應用:在基礎癌症研究中擴大採用患者來源的異種移植(PDX)模型
患者來源的異質骨移植(PDX)模型在基礎癌症研究中非常有價值,因為它們忠實地模擬了腫瘤環境和患者異質性。生物標記分析對於識別預測和預後標記以指導個別患者的治療決策至關重要。 PDX 模型透過捕捉腫瘤生長和治療反應的分子變化來實現全面的生物標記開發。臨床前藥物開發在很大程度上依賴 PDX 模型來評估臨床實驗藥物的安全性、有效性和藥物動力學特性。 PDX模型概括了人類癌症的複雜性和多樣性,因此是進入臨床試驗前評估抗癌藥物的首選。
最終用戶:提高學術和研究機構中患者來源的異質骨移植的適用性
學術和研究機構主要促進癌症生物學、藥效測試和個人化醫療開發的研究。這些機構使用 PDX 模型來識別新的治療標靶並了解腫瘤進展的機制。委外研發機構(CRO) 使用 PDX 模型進行藥物發現和研發,為製藥和生物技術公司提供臨床前和臨床測試服務。 CRO 將這些模型應用於藥物開發的各個階段,包括標靶辨識/驗證、先導藥物最適化、藥物動力學/動態(PK/PD) 測試和毒性評估。製藥和生物技術公司正在採用 PDX 模型來支持其藥物發現管道並滿足個人化癌症治療的需求。
區域洞察
由於政府的支持措施以及促進該領域進步的各種研究機構的存在,美洲的 PDX 市場高度發展。此外,該地區的生物技術公司在為藥物發現和個人化醫療方法提供 PDX 服務方面具有巨大價值。在歐盟 (EU),歐盟資助的計劃重點在於擴大成員國對 PDX 模型的使用。中東地區對 PDX 建模研究的興趣與日俱增,各組織紛紛採取舉措,為臨床前癌症模型開發開發專業知識和資源。在亞太地區,生物醫學研究的投入帶動了國內藥廠PDX模型研究的激增。亞太地區的政府框架也支持促進 PDX 模型研究的舉措,為患者來源的異質骨移植/PDX 模型市場開發潛在平台。
FPNV定位矩陣
FPNV定位矩陣對於評估患者來源的異質骨移植/PDX模型市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對患者異質骨移植/PDX 模型市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭力評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.患者異質骨移植/PDX模型市場的市場規模和預測是多少?
2.在病患異質骨移植/PDX模型市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.人異質骨移植/PDX模型市場的技術趨勢與法規結構是什麼?
4.在病患異質骨移植/PDX模型市場中主要供應商的市場佔有率是多少?
5. 進入病人源性異質骨移植/PDX模型市場的合適型態和策略手段是什麼?
[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.
A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 222.26 million |
Estimated Year [2024] | USD 253.51 million |
Forecast Year [2030] | USD 574.99 million |
CAGR (%) | 14.54% |
Type: Extensive use of mouse models in oncology to develop novel therapeutics
Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.
Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.
Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.
End-User: Rising applicability of patient-derived xenografts in academic and research institutes
Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.
Regional Insights
The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?
3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?
4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?
5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?